These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 10640512)
1. Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs. Plum A; Agerso H; Andersen L Drug Metab Dispos; 2000 Feb; 28(2):155-60. PubMed ID: 10640512 [TBL] [Abstract][Full Text] [Related]
2. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study. Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369 [TBL] [Abstract][Full Text] [Related]
3. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803 [TBL] [Abstract][Full Text] [Related]
4. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Sonaje K; Lin KJ; Wey SP; Lin CK; Yeh TH; Nguyen HN; Hsu CW; Yen TC; Juang JH; Sung HW Biomaterials; 2010 Sep; 31(26):6849-58. PubMed ID: 20619787 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. Zhang SQ; Zhong XY; Lu WL; Zheng L; Zhang X; Sun F; Fu GY; Zhang Q J Inorg Biochem; 2005 May; 99(5):1064-75. PubMed ID: 15833329 [TBL] [Abstract][Full Text] [Related]
6. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253 [TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic and pharmacodynamic studies of human insulin and analogues in chronic diabetic Yucatan minipigs. Lin S; Chen LL; Chien YW J Pharmacol Exp Ther; 1998 Aug; 286(2):959-66. PubMed ID: 9694956 [TBL] [Abstract][Full Text] [Related]
8. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats. Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510 [TBL] [Abstract][Full Text] [Related]
9. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Perriello G; Pampanelli S; Porcellati F; Avogaro A; Bosi E; Petrella G; Squatrito S; Furneri S; Marra G; Vitali L; Previti M; Cucinotta D Diabet Med; 2005 May; 22(5):606-11. PubMed ID: 15842516 [TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp. Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509 [TBL] [Abstract][Full Text] [Related]
12. Comparative clinical pharmacology of human insulin (Novo) and porcine insulin in normal subjects. Ebihara A; Kondo K; Ohashi K; Kosaka K; Kuzuya T; Matsuda A Diabetes Care; 1983; 6 Suppl 1():17-22. PubMed ID: 6343032 [TBL] [Abstract][Full Text] [Related]
13. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011 [TBL] [Abstract][Full Text] [Related]
14. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977 [TBL] [Abstract][Full Text] [Related]
15. Clinical strategies for controlling peaks and valleys: type 1 diabetes. Bolli GB Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610 [TBL] [Abstract][Full Text] [Related]
16. State of insulin self-association does not affect its absorption from the pulmonary route. Hussain A; Ahsan F Eur J Pharm Sci; 2005 Jun; 25(2-3):289-98. PubMed ID: 15911225 [TBL] [Abstract][Full Text] [Related]
18. Feasibility of microneedles for percutaneous absorption of insulin. Ito Y; Hagiwara E; Saeki A; Sugioka N; Takada K Eur J Pharm Sci; 2006 Sep; 29(1):82-8. PubMed ID: 16828268 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Porcellati F; Rossetti P; Ricci NB; Pampanelli S; Torlone E; Campos SH; Andreoli AM; Bolli GB; Fanelli CG Diabetes Care; 2007 May; 30(5):1261-3. PubMed ID: 17303785 [No Abstract] [Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Kaku K; Matsuda M; Urae A; Irie S Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]